This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nurses seemingly have a leg up when it comes to branching into medical sales. After all, medical sales seem like a very different animal from nursing. One involves helping patients, while the other requires you to meet sales quotas. One involves helping patients, while the other requires you to meet sales quotas.
The LSIMF was announced within an overall investment of £354 million for life sciences manufacturing, said MMIP, which added it will be “important to understand how and when the remaining £294 million will be allocated.” ” Image from the Association of the British Pharmaceutical Industry (ABPI).
When questioned about which technologies he considered have potential to advance the sector, Chornet emphasised that not only is mRNA as a vaccine technology “a very promising and interesting platform [but that it is] disruptive and a game changer technology for vaccine [manufacturing] and overall biotech.”
Bob is a life sciences and technology marketing leader with more than 25 years of experience working directly for pharmaceuticalmanufacturers (Merck, AstraZeneca, and Shire) and for technology companies that serve the industry (Appature, IQVIA, and Sparta). The post Bob Harrell appeared first on Pharma Marketing Network.
In response to the draft pandemic treaty text , the People’s Vaccine, a coalition of organisations and networks that is campaigning to make a vaccine available free of charge to everyone, called for IP to be waived for future products developed against pandemics.
In an age of disruption, technology is key to enabling pharmaceuticalmanufacturers monitor, track and control shipments and their processes. Pharmaceutical firms are changing the way they do business; the future winners will be highly automated and digitalised.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content